Compare GSM & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | IVVD |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.0M | 692.7M |
| IPO Year | N/A | 2021 |
| Metric | GSM | IVVD |
|---|---|---|
| Price | $4.63 | $2.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $8.33 |
| AVG Volume (30 Days) | 1.6M | ★ 4.9M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,373,244,000.00 | $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | $22.56 | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $2.97 | $0.35 |
| 52 Week High | $5.74 | $3.07 |
| Indicator | GSM | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 55.26 |
| Support Level | $4.42 | $2.15 |
| Resistance Level | $4.77 | $2.59 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 62.00 | 60.40 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.